Stockscreener 앱 받기
18.84
2.66%
-0.515
전일 마감가:
$19.36
열려 있는:
$19.02
하루 거래량:
876.12K
Relative Volume:
0.29
시가총액:
$2.40B
수익:
$236.00M
순이익/손실:
$-369.00M
주가수익비율:
-5.9209
EPS:
-3.1828
순현금흐름:
$-489.00M
1주 성능:
-14.81%
1개월 성능:
-28.59%
6개월 성능:
-25.01%
1년 성능:
+12.31%
1일 변동 폭
$18.43
$19.09
1주일 범위
$17.43
$24.70
52주 변동 폭
$16.41
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
18.84 | 2.40B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
526.09 | 133.34B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.65 | 82.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
203.14 | 81.10B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
870.00 | 54.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.57 | 42.37B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-16 | 개시 | William Blair | Outperform |
| 2026-10-14 | 개시 | JP Morgan | Overweight |
| 2026-09-16 | 개시 | TD Cowen | Buy |
| 2026-05-18 | 재개 | Truist | Buy |
| 2026-02-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Why is Arcus Biosciences stock sliding today? By Investing.com - Investing.com Canada
Arcus Biosciences Prices $250 Million Common Stock Offering; Shares Down Pre-Bell - marketscreener.com
Arcus Biosciences reports $694M cash for pipeline advancement through pivotal trials - The Clinical Trial Vanguard
Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock - TradingView
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - Yahoo Finance
Arcus Biosciences (RCUS) Shares Plunge Nearly 20% Amid Clinical Data Release and Stock Offering - GuruFocus
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Arcus Biosciences stock falls on public offering announcement - Investing.com
Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences launches public offering of common stock By Investing.com - Investing.com Canada
Citi reiterates buy rating on Arcus Biosciences after stock drops 20% - StreetInsider
Arcus Biosciences launches public offering of common stock - StreetInsider
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - Morningstar
Arcus Biosciences announces public stock offering - TradingView
A public stock offering has begun at Arcus Biosciences, but its size and completion remain uncertain. - Stock Titan
Arcus Biosciences Drops 5.5% After Truist Securities Maintains Buy - AlphaStreet
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal - Yahoo Finance
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead (NYSE:RCUS) - Seeking Alpha
Arcus stock rises on ARC-20 data for kidney cancer drug (RCUS) - Seeking Alpha
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer - BioSpace
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo Finance
Arcus Biosciences Drops 6.1% Amid Sector-Wide Selling - AlphaStreet
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo! Finance Canada
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage? - Yahoo Finance
Arcus Biosciences stock falls 2.79 percent before ARC-20 data - ad-hoc-news.de
Arcus Biosciences stock gains 1.49 percent ahead of data event - ad-hoc-news.de
Wall Street Zen upgrades Arcus Biosciences stock to Hold - ad-hoc-news.de
How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data - Yahoo Finance
Arcus Biosciences (RCUS) Pulls Back 3.13% to $24.44, Testing Key SupportBreak of Structure - siam.in
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Wedbush Reiterates Arcus Biosciences At Outperform, Sets Price Target Of $43, Casdatifan Data Ahead - RTTNews
RCUS Reiterated by Wedbush -- Price Target Maintained at $43.00 - GuruFocus
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Arcus Biosciences, Inc. (RCUS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo! Finance Canada
Arcus Biosciences Announces New Employment Inducement Grants - finance.yahoo.com
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance Singapore
Arcus Biosciences stock trades 16.8 percent below yearly high - AD HOC NEWS
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RCUS Looks 292.6% Overvalued on GF Value™ - GuruFocus
Cantor Fitzgerald reiterates Arcus Biosciences stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Arcus Biosciences stock rating - Investing.com
New kidney cancer data from 121 patients will be shared Oct. 20 - Stock Titan
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - Yahoo Finance
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arcus Biosciences Inc 주식 (RCUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Azoy Alexander | Chief Accounting Officer |
Aug 21 '26 |
Sale |
30.00 |
2,827 |
84,810 |
39,581 |
| ALEXANDER AZOY | Officer |
Aug 21 '26 |
Proposed Sale |
29.52 |
2,827 |
83,453 |
0 |
| Jaen Juan C. | President |
Jul 10 '26 |
Sale |
28.62 |
20,067 |
574,288 |
822,240 |
| Juan Jaen | Officer |
Jul 09 '26 |
Proposed Sale |
29.96 |
25,000 |
749,000 |
0 |
| Jaen Juan C. | President |
Jul 09 '26 |
Sale |
30.05 |
48,502 |
1,457,631 |
842,307 |
| Juan Jaen | Officer |
Jun 24 '26 |
Proposed Sale |
28.80 |
50,000 |
1,440,000 |
0 |
| Jaen Juan C. | President |
Jun 24 '26 |
Sale |
29.66 |
6,431 |
190,740 |
890,809 |
| Jaen Juan C. | President |
Jun 23 '26 |
Sale |
27.73 |
15,764 |
437,100 |
897,240 |
| Juan Jaen | Officer |
Jun 22 '26 |
Proposed Sale |
27.23 |
25,000 |
680,750 |
0 |
| Jaen Juan C. | President |
Jun 22 '26 |
Sale |
27.03 |
9,236 |
249,661 |
913,004 |
2.78%
0.44%
자본화:
|
볼륨(24시간):